

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Tumors classified as invasive lobular carcinoma are typically of which subtype?
 - a. ER-negative, HER2-negative
 - b. ER-negative, HER2-positive
 - c. ER-positive, HER2-negative
 - d. ER-positive, HER2-positive
2. The goal of the MINDACT trial, for which initial results were recently published, was to evaluate the benefit of genomic profiling with the _____ in addition to standard clinical-pathological criteria for patients with early BC and 0 to 3 positive lymph nodes who might safely forgo chemotherapy without compromising outcome.
 - a. PAM50 assay
 - b. 70-gene signature
 - c. 21-gene signature
3. A recent meta-analysis evaluating the use of adjuvant bisphosphonates for women with early BC pointed toward a reduction in the odds of disease recurrence in women who were _____ when they began treatment.
 - a. Premenopausal
 - b. Postmenopausal
4. The SSO-ASTRO-ASCO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma in Situ states that clear margins wider than 2 millimeters result in significantly lower rates of recurrence.
 - a. True
 - b. False
5. The ongoing POSITIVE study is evaluating recurrence risk of interrupting endocrine therapy for young women with endocrine-responsive BC who desire pregnancy.
 - a. True
 - b. False
6. The DCIS Score for patients with DCIS who have undergone local excision is predictive of _____.
 - a. The risk of DCIS recurrence
 - b. The risk of invasive BC
 - c. Both a and b
7. Results of the low-risk registry of the TAILORx trial, which is evaluating adjuvant endocrine therapy with or without chemotherapy for patients with ER-positive, HER2-negative BC based on the 21-gene signature, reported an approximate _____ risk of distant recurrence at 5 years for patients with a low RS of less than 11 who received endocrine therapy alone without chemotherapy.
 - a. 0.1%
 - b. 1.0%
 - c. 10.0%
8. The Phase III _____ study randomly assigns patients with hormone receptor-positive, HER2-negative BC, 1 to 3 positive nodes and a 21-gene RS of 25 or lower to adjuvant endocrine therapy with or without chemotherapy.
 - a. ECOG-E2108
 - b. POSITIVE
 - c. RxPONDER
9. Results of the Phase III West German Study Group PlanB trial demonstrated a 5-year disease-free survival rate of 94% in patients with ER-positive, HER2-negative, _____ BC who did not receive adjuvant chemotherapy based on an RS of 11 or lower.
 - a. High-risk node-negative
 - b. Node-positive
 - c. Both a and b
10. The Phase III CALOR trial evaluating adjuvant chemotherapy for isolated local or regional recurrence of BC demonstrated a significant improvement in survival for patients who received chemotherapy.
 - a. True
 - b. False